
First quarter 2026
Q1 2026 results were reviewed by management during a live audio webcast with the financial community on April 23, 2026. The presentation was followed by a Q&A session.
Press Releases
April 23, 2026
Press Release: Q1 2026: double-digit sales and business EPS growth
April 22, 2026
Press Release: Sanofi and Regeneron’s Dupixent approved in the US as the first biologic medicine for young children with uncontrolled chronic spontaneous urticaria
April 22, 2026
Press Release: Sanofi's Tzield approved in the US to delay the onset of stage 3 type 1 diabetes in young children
Upcoming Events
24Mar
2026
BNP Paribas Healthcare Conference – London
Conferences
26Mar
2026
Goldman Sachs 9th Annual Biopharma Innovation Summit – London
Conferences
29Apr
2026
Annual General Meeting 2026
The Sanofi General Meeting will be held on April 29, 2026 at 2:30p.m CET at the Palais des Congrès in Paris.
14:30 - 16:30 CET
Annual general meetings

30th Consecutive Year of Dividend Increase

Environment, Social, Governance
As a global pharmaceutical company, we stretch everyday to deliver safe and sustainable innovation and play our part in addressing some of the world’s most pressing challenges.
Contact Our Investor Relations Team
For general inquiries
Please contact the switchboard, +33 (0)1 53 77 40 00
